These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. [Antithrombotic therapy for ischemic cerebrovascular accident]. Mas JL Arch Mal Coeur Vaiss; 2002 Nov; 95 Spec No 7():53-7. PubMed ID: 12500606 [TBL] [Abstract][Full Text] [Related]
48. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538 [TBL] [Abstract][Full Text] [Related]
49. Rationale for low-molecular weight heparin in coronary stenting. Zidar JP Am Heart J; 1997 Nov; 134(5 Pt 2):S81-7. PubMed ID: 9396639 [TBL] [Abstract][Full Text] [Related]
50. Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736 [TBL] [Abstract][Full Text] [Related]
51. Role of platelet inhibitor therapy in myocardial infarction. Stein B; Fuster V Cardiovasc Drugs Ther; 1989 Dec; 3(6):797-813. PubMed ID: 2487543 [TBL] [Abstract][Full Text] [Related]
53. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. van Es RF; Jonker JJ; Verheugt FW; Deckers JW; Grobbee DE; Lancet; 2002 Jul; 360(9327):109-13. PubMed ID: 12126819 [TBL] [Abstract][Full Text] [Related]
54. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317 [TBL] [Abstract][Full Text] [Related]
55. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Weinberger J Drugs; 2005; 65(4):461-71. PubMed ID: 15733010 [TBL] [Abstract][Full Text] [Related]
56. Antithrombotic agents in coronary artery disease. Resnekov L; Chediak J; Hirsh J; Lewis D Chest; 1986 Feb; 89(2 Suppl):54S-67S. PubMed ID: 3510831 [No Abstract] [Full Text] [Related]
57. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Hacke W Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184 [TBL] [Abstract][Full Text] [Related]
58. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. Oler A; Whooley MA; Oler J; Grady D JAMA; 1996 Sep; 276(10):811-5. PubMed ID: 8769591 [TBL] [Abstract][Full Text] [Related]
59. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Rubboli A; Milandri M; Castelvetri C; Cosmi B Cardiology; 2005; 104(2):101-6. PubMed ID: 16020950 [TBL] [Abstract][Full Text] [Related]
60. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Harrington RA; Becker RC; Ezekowitz M; Meade TW; O'Connor CM; Vorchheimer DA; Guyatt GH Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]